Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Cystic Fibrosis (September 2016)

Posted by Matt Breese on Sep 8, 2016

Find me on:

According to our recent payer coverage analysis for CF treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access by channel shows that health exchange and medicare formularies are more restrictive than commercial formularies, with roughly 3/4 of payer-controlled pharmacy benefit lives restricted by a PA or step therapy or not covered entirelyreality-check-cf-september.png

Source: MMIT data as of Q3 2016

Trends: One trend is the positive results that prescribers see with new treatments in the market. While many U.S. prescribers and patients rely on their health plan to cover these life-saving medications, countries in Europe prevent some therapies from hitting the market due to their high cost. Another trend is the continued partnership betwene pharma, providers and specialty pharmacies. Pharmacists are helping to accelerate the time-to-treatment for patients.

To read the full Reality Check on cystic fibrosis with key findings on clinical characteristics, CF drug market access and payer coverage, please click on the button below: 

View Reality Check

Topics: Market Access, Branding & Marketing